Advancing Antibody Drug Discovery (ABvance)
This project generated novel Ab structures and addressed the need for improved Ab structural data sharing to accelerate drug discovery
Overview
This project set out to generate novel Ab structures and improve Ab structural data sharing across the life sciences. The objective was to increase researchers’ predictive power and their ability to accurately model Ab structures; considerably reducing the time and cost associated with generating experimental data to support decision-making in drug projects.
A major project milestone involved 12 antibody structures being deposited into the European Bioinformatics Institute’s (EMBL-EBI) Protein Data Bank (PDB).
Humans are capable of producing 10 billion distinct Ab molecules, and at the inception of the project there were only around 3,000 Ab structures in the public domain. This data is fundamental in drug discovery. This led the Pistoia Alliance and its members to address some of the considerable gaps that exist in the collective understanding of a typical human Ab repertoire which is key to the design of high quality candidates during the discovery of biologic drugs.
Deliverables and Resources
View All Resources
Our Events
Pharma and Life Science AI/ML Training Session 1: Introduction to AI for Drug Discovery
Book Now
Pharma and Life Science AI/ML Training – Session 2: Generative AI for Drug Development
Book Now
Partner Event: Semantic Data Europe 2025: Taxonomy, Ontology, and Knowledge Graphs
Book Now
Pharma and Life Science AI/ML Training – Session 6: LLMs as Agents in Drug Discovery
Book Now
Pharma and Life Science AI/ML Training – Session 7: AI in Computational Medicinal Chemistry
Book Now
Pharma and Life Science AI/ML Training – Session 9: Digital Pharmaceutical Manufacturing
Book Now
